TB511 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary clinical trials.
This trial tests a new drug called TB511, either alone or combined with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- Your cancer must be an advanced solid tumor that has not responded to or you couldn't tolerate standard treatments.
- If you've had immunotherapy (like PD-1 or PD-L1 inhibitors) and it stopped working or you had severe side effects, you may qualify for the combination therapy part of the trial.
- You need to have at least one tumor that can be measured on a scan (like a CT or MRI).
- You should be able to take care of yourself (ECOG performance status 0 or 1) — generally, you're up and about, though you may need some help.
- You must agree to use highly effective birth control during the trial and for 6 months after treatment ends (if you or your partner can become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to see how safe the drug is and how the body processes it, and it may offer a new option for those with few alternatives.
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests an experimental drug, BNT3214, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if BNT3214 is safe and helps shrink tumors.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.